Publication | Open Access

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

UrologyGenitourinary CancerMedicinePharmacologyClinical TrialsEcog-acrin E2805Non-metastatic Renal-cell CarcinomaCancer TreatmentAdjuvant SunitinibOncologyMolecular Oncology